Who Paid My Doc
Carvykti
Drug Oncology
NDC 57894-111-01
General payments
$9,844,837
Research payments
$32,457,974
Through program year 2025, $9,844,837 in general payments and $32,457,974 in research payments were reported against Carvykti (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $7,297,028 | 15,585 |
| 2025 | Research | $9,085,386 | 1,273 |
| 2024 | General | $1,133,147 | 5,379 |
| 2024 | Research | $8,072,168 | 925 |
| 2023 | General | $1,181,804 | 1,939 |
| 2023 | Research | $8,153,837 | 915 |
| 2022 | General | $228,958 | 203 |
| 2022 | Research | $7,146,583 | 598 |
| 2021 | General | $3,900 | 12 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 106 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 52 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
23,118 general · 3,711 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.